Moxalactam

Summary

Moxalactam (CHEMBL74632) is an approved small-molecule antibacterial drug (ATC J01DD06); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DD06
• Indications: 1 condition
• Chemistry: 520.5 Da · C20H20N6O9S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL74632
Name	Moxalactam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	47499
ChEBI	CHEBI:599928
ATC	J01DD06
Molecular formula	C20H20N6O9S
Molecular weight	520.5
InChIKey	JWCSIUVGFCSJCK-CAVRMKNVSA-N

SMILES: CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O

IUPAC name: (6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Latamoxef, moxalactam, Moxalactam, MOXALACTAM, latamoxef

Parent form; salt/anhydrous children: CHEMBL1200357

Patent coverage: 1,441 distinct patent families (4,569 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prostaglandin G/H synthase 1, Solute carrier family 15 member 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS1	5.03	AC50	9250	nM	CHEMBL_ACT_25205068

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).